Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC

Table 2 OS Proportional Hazards Model: significant variables and estimated parameters

Variable	Category	Degrees of freedom	Parameter estimate	SE	Chi-square (Wald)	Pr > Chi-square	Hazard Ratio (HR)	HR 95% confidence interval
ECOG-PS 0	no^a	1		0.36			1
ECOG-PS 0	yes	1	−0.810	0	5.070	0.024	0.45	0.22	0.90
Cutaneous toxicity	no^a	1		0.36			1
Cutaneous toxicity	yes	1	−1.019	5	7.783	0.005	0.36	0.18	0.74
Endocrinological toxicity	no^a	1		0.60			1
Endocrinological toxicity	yes	1	−1.712	4	8.040	0.005	0.18	0.06	0.59

ECOG-PS Eastern Cooperative Oncology Group Performance Status, SE Standard Error
^aReference category

ISSN: 2050-6511